Strategic partnerships Substipharm actively engages in manufacturing and distribution partnerships with global players (e.g., Emergent BioSolutions) to co-develop and supply vaccines, presenting a strong avenue for sales reps to pursue co-marketing, licensing, and contract manufacturing opportunities.

Vaccine focus A notable emphasis on vaccines, including IMOJEV for Japanese encephalitis, suggests opportunities in vaccine manufacturing, distribution, and regional access initiatives across Asia and the US markets via strategic distributors and government contracts.

Diversified portfolio With mature brands, generics, OTC, difficult-to-develop medicines, and biologics, Substipharm offers multiple entry points for sales motions—from line extensions and value-added formats to vaccine collaborations and niche therapeutics.

Global footprint Operations and licensing in over 90 countries indicate a scalable distribution network and potential for multi-region deals, regional exclusivity opportunities, and leverage with local distributors or governmental tenders.

Growth signals Recent high-profile partnerships and an expanding development pipeline (50+ projects) imply a trajectory of scale and innovation, creating opportunities for strategic funding discussions, joint development ventures, and portfolio expansion deals.